Vistagen Therapeutics (NASDAQ: VTGN) files 8-K on fiscal 2026 Q2 results

Rhea-AI Filing Summary

Vistagen Therapeutics, Inc. reported that it released its financial results for its fiscal year 2026 second quarter, which ended on September 30, 2025. The company disclosed that these results were announced in a press release dated November 13, 2025, which is included with this report as Exhibit 99.1.

The report explains that the press release and related information are being furnished, not filed, meaning they are not automatically subject to certain Exchange Act liabilities or incorporated into other securities filings unless specifically referenced.

FALSE000141168500014116852024-09-232024-09-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 13, 2025

Vistagen Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Nevada			000-54014			20-5093315
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification Number)

343 Allerton Ave.

South San Francisco, California 94080

(Address of principal executive offices)

(650) 577-3600

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.001 per share			VTGN			Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2)

Emerging Growth Company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act o

Item 2.02 Results of Operations and Financial Condition.

On November 13, 2025, Vistagen Therapeutics, Inc. (the “Company”) issued a press release announcing financial results for its fiscal year 2026 second quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Disclaimer.

The information contained in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits Index

Exhibit No.						Description
99.1						Press Release issued by Vistagen Therapeutics, Inc., dated November 13, 2025, furnished herewith
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Vistagen Therapeutics, Inc.
Date: November 13, 2025			By:			/s/ Shawn K. Singh
						Shawn K. Singh President and Chief Executive Officer

FAQ

What did Vistagen Therapeutics (VTGN) report in this 8-K?

Vistagen Therapeutics, Inc. reported that it issued a press release announcing financial results for its fiscal year 2026 second quarter, and furnished that release as Exhibit 99.1.

Which period do the VTGN results in the press release cover?

The press release covers Vistagen Therapeutics, Inc.'s financial results for its fiscal year 2026 second quarter, which ended on September 30, 2025.

When did Vistagen Therapeutics (VTGN) issue the earnings press release?

Vistagen Therapeutics, Inc. issued the press release announcing its fiscal 2026 second quarter results on November 13, 2025.

Where can investors find the detailed VTGN Q2 fiscal 2026 financial results?

The detailed financial results are contained in the press release furnished as Exhibit 99.1 to this report.

Is the Vistagen Therapeutics (VTGN) press release considered filed with the SEC?

No. The company states that the information in this report and Exhibit 99.1 is being furnished and is not deemed "filed" for purposes of Section 18 of the Exchange Act.

Who signed the Vistagen Therapeutics (VTGN) 8-K for the Q2 fiscal 2026 results?

The report was signed on behalf of Vistagen Therapeutics, Inc. by Shawn K. Singh, the company's President and Chief Executive Officer, dated November 13, 2025.